Saturday, October 3, 2026

Copper Bullish Momentum: 0.3% Up Since The Last Session

ViaNews Editorial Team

January 6, 2021

Copper Bullish Momentum: 0.3% Up Since The Last Session

Copper is currently on bullish momentum. At 19:00 EST on Tuesday, 5 January, Copper is at $3.65 and 0.3% up since the last session's close.

Copper Range

Copper is 2.657% up from its last session low of $3.56 and 2.384% up from its last session high of $3.57.

Copper is 2.38% up from its last three sessions higher value of $3.57 and is 4.14% up from its last three sessions lower value of $3.51.

Copper is 2.00% up from its last seven sessions higher value of $3.58 and is 4.14% up from its last seven sessions lower value of $3.51.

Copper is 0.14% up from its last month's higher value of $3.65 and is 4.51% up from its last month's lower value of $3.49.

Volatility

Copper's last day, last week, and last month's average volatility was 1.39%, 0.14%, and 0.27%, respectively.

Copper's last day, last week, and last month's high and low average amplitude percentage was 0.27%, 0.55%, and 0.63%, respectively.

Last news about Copper

Surge copper appoints leif nilsson as chief executive officer. According to Business Insider on Monday, 4 January, "VANCOUVER, BC, Jan. 4, 2021 /CNW/ - Surge Copper Corp. (TSXV: SURG) ("Surge" or the "Company") is pleased to announce the appointment of Leif Nilsson as Chief Executive Officer of Surge. ", "The Company owns a 100% interest in the Ootsa Property, an advanced stage exploration project containing the East Seel, West Seel and Ox porphyry deposits located adjacent to the open pit Huckleberry Copper Mine, owned by Imperial Metals. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com